Clinical Trials at CHR
Medically reviewed by Norbert Gleicher, MD, FACOG, FACS - Written by CHR Staff - Updated on Jun 26, 2014
Human Growth Hormone for Enhancement of Ovulation Induction in IVF
Human Growth Hormone in IVF Study: Summary
CHR is conducting a open-label, prospectively randomized clinical trial on the effects of human growth hormone (HGH) used in conjunction with ovulation induction for in vitro fertilization (IVF). The aim of this study is to determine whether adding human growth hormone during the early stage of follicle development improves ovarian response to gonadotropin stimulation for IVF. Patients who have failed to respond to ovarian stimulation while on DHEA supplementation, or had 2 eggs or fewer, will be invited to participate in the HGH trial.
- Contact us for more information on human growth hormone (HGH) trial
- Read about HGH in April 2014 issue of CHR VOICE
Human Growth Hormone IVF Clinical Trial
Dr. Barad explains the human growth hormone clinical trial. (About 17 minutes.)
Human Growth Hormone and Ovarian Reserve Clinical Trial Overview
After years of revolutionary research on the positive effects of DHEA on ovarian reserve, CHR now routinely recommends DHEA supplementation to women of all ages with diminished ovarian reserve (DOR). While DHEA supplementation has helped many women conceive with their own eggs, both here at CHR at other centers that have adopted our DHEA protocol, there are still women whose ovarian reserve is so low that even DHEA supplementation is not enough. After careful review of literature, CHR is now investigating a new protocol to help this group of women, involving human growth hormone (HGH) as an adjuvant to ovarian stimulation with gonadotropins.
What Is Human Growth Hormone?
Human growth hormone (HGH) is a hormone that raises blood sugar, free fatty acids and insulin-like growth factors (IGFs), which stimulates the production of proteins. HGH as a medication is best known for its use in short-stature children.
HGH and IGFs closely interact. HGH stimulates the production of IGF-1, one of the two IGFs. This HGH-IGF "axis" plays an important role in cell proliferation and inhibits apoptosis (cell death). This "axis" has been associated with a number of normal physiological processes, including follicle maturation (growth of eggs) in the ovaries.
How Might Human Growth Hormone Improve Ovarian Reserve?
This is an area of controversy, with conflicting results from studies trying to determine the efficacy of HGH use as an adjuvant to gonadotropins in ovarian stimulation. After a careful review of the published data, CHR has decided that the likely reason behind the conflicting reports is the poor timing of HGH administration. Administering HGH for only a short period of time during or before stimulation, most of the published studies missed the most important time period, when the follicles are still small and are most receptive to IGF-1's proliferative effects.
In an analogy to DHEA supplementation, CHR investigators hypothesized that HGH may be more effective if administered at least 6-8 weeks before the IVF cycle starts, targeting these small, growing follicles. At this stage, CHR investigators believe that HGH may be able to improve the quality of eggs in the follicles, and this is the hypothesis of this clinical trial.
How Can I Participate in HGH Clinical Trial?
HGH clinical trail is offered to patients who are under 45 years of age, who have either failed to respond to CHR's standard ovarian stimulation while on DHEA supplementation, or who produced 2 or fewer eggs under the same protocol. If you are eligible for the study, your clinical coordinator will ask you if you want to participate in the study. If you agree to participate, you will need to sign an informed consent, after which you will be randomized into either the study group, which receives HGH injections, or the control group, which does not receive anything (no "fake" injections).
Additional Cost to Participate in HGH Clinical Trial
Unfortunately, human growth hormone is an expensive drug. We estimate about $6,000 of additional cost to patients who are randomized to the HGH arm of the trial.
Want to know more?
To learn more about the HGH trial at CHR, simply complete the contact form.
Norbert Gleicher, MD, FACOG, FACS
Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.